.jpg "Aurinia Pharmaceuticals (NASDAQ: AUPH)")
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) yesterday and set a price target of $16. The company’s shares closed yesterday at $6.28.
According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.2% and a 52.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Currently, the analyst consensus on Aurinia Pharmaceuticals is Strong Buy and the average price target is $13, representing a 107.0% upside.
In a report issued on May 2, H.C. Wainwright also maintained a Buy rating on the stock with a $12 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.68 and a one-year low of $4.41. Currently, Aurinia Pharmaceuticals has an average volume of 626.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Read More on AUPH:
